5 Big Pharma Stocks With the Best Drug Pipelines
Big pharma companies can't rest on their laurels. Continual research and development is critical to ensure long-term success. Some of that R&D pays off more than others, though.
Market research firm EvaluatePharma recently released its report looking at the state of the biopharmaceutical industry five years from now. One key area the firm researched was the potential value creation from pipeline products between now and 2022. Here's why Roche (NASDAQOTH: RHHBY), AstraZeneca (NYSE: AZN), AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) ranked at the top.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
148,28 €
-0,34 %
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.
